RESEARCH Towards. an HIV Cure RESER RVOIRS CURE CURE CURECURE. Symposium RESERVOIR INDUSTRY GLOBAL GLOBAL BAL GLOBAL RESEARCH RESEARCH INDUS

Transcription

1 CU G IN GLOBAL GLOB I GLOBAL IR an HIV Cure ER GLOBAL RCH Symposium USTR US US US S R GLO RY GLOBAL RE RES 2014 Towards R IR US 19 & 20 July 2014 Melbourne, Victoria University, City Convention Centre 300 Flinders Street, Melbourne, US US GLO OIRS towards an cure people focused science driven BAL US

2 CU GLOB G IN GLOBAL I USTR ER GLOBAL GLOBAL US US US IR Office of AIDS Research RCH 2014 Symposium Sponsors: S R GLO RY US IR GLOBAL RE RES The IAS would like to thank the following organizations for their generous support to the 2014 Towards an HIV Cure Symposium: US Scientific Partners & Initiative Sponsors: Abstracts Embargo Policy US GLO OIRS Most abstracts presented at the symposium will also be presented at the AIDS 2014 Conference. The Conference Embargo Policy states that all oral abstracts accepted R for inclusion at AIDS 2014 may not be published before the start date and time of the session at AIDS 2014 in which the oral abstract is being presented. The session dates and times of those abstracts being presented at AIDS 2014 are clearly indicated beside the abstract title in this programme book. In line with the Conference Embargo Policy, any uploading of abstract presentations CONTENT (images, text, video, audio) is STRICTLY FORBIDDEN until the start date and time of the session at AIDS 2014 in which the abstract is being presented. BAL US

3 Contents GLOBAL SEARCH WELCOME STATEMENT 2 Programme Committee 3 19 july Opening Session 4 Clearing HIV-Infected Cells: Kill 4 Reversing Latent HIV: Shock 5 Roundtable: Analytical Treatment Interruption in HIV Cure Research 6 Why Does HIV Persist on ART? 6 Poster Exhibition & Networking Session 7 20 july Roundtable: Preparedness for HIV Cure in Resource-Limited Settings 8 Where Does HIV Persist on ART? 8 Roundtable: Public and Private Partnerships in HIV Cure Research 9 Closing Session 9 POSTER EXHIBITION List of abstracts displayed Scholarship recipients 15 IAS/ANRS Young Investigator Award 16 IAS Towards an HIV Cure Timeline 17 Programme at a glance 18 ARCHU GL Download the symposium abstract book directly using the QR code or visit 1

4 Welcome GLOBAL Statement SEARCH Dear Colleagues, ARCHU On behalf of the International AIDS Society (IAS), the Programme Committee, and all members of the Towards an HIV Cure initiative, it is our pleasure to welcome you to Melbourne for the 2014 Towards an HIV Cure Symposium. Following the success of the symposium in 2012 in Washington, D.C. and 2013 in Kuala Lumpur, we are delighted to organize a new edition in 2014 to provide an interactive and informative meeting for basic and clinical researchers, social scientists and community members involved in HIV cure research world-wide. Research on viral persistence under antiretroviral therapy and on strategies towards an HIV Cure is moving fast and generates a great deal of scientific excitement. The two-day symposium will include invited speakers, oral and poster abstract presentations as well as roundtable discussions, to present and discuss the most recent results in the field and look ahead together at future research directions. We are confident that once again the symposium will be a platform where the international HIV/AIDS community will be able to share their knowledge, debate and network. The symposium is open to senior, mid-career and junior scientists, clinical researchers, community representatives, research funding administrators and scientific journalists, and registrations were purposely limited to 270 to ensure good interaction between the participants. The symposium places strong emphasis on ensuring representation of scientific excellence and community globally, with scholarships being provided to more than 40 participants worldwide. In order to disseminate the information shared at this symposium, the issues and findings will be disseminated through the publication of the presented abstracts and audio recordings on the IAS website. We look forward to a thought-provoking and fruitful meeting. GL Sincerely, Pr. Françoise Barré-Sinoussi Symposium Co-Chair IAS President Dr. Steven Deeks Symposium Co-Chair Pr. Sharon Lewin Symposium Co-Chair 2

5 GLOBAL SEARCH 2014 Programme Committee Françoise Barré-Sinoussi (Chair) Inserm and Institut Pasteur ARCHU France Steven Deeks (Chair) University of California, San Francisco Usa Sharon Lewin (Chair) The Alfred Hospital, Monash University and Burnet Institute Jintanat Ananworanich Us Military Hiv Research Program Brigitte Autran University Pierre et Marie Curie, Paris France David Evans Project Inform Usa Romas Geleziunas Gilead Sciences Inc. Usa Jennifer Hoy The Alfred Hospital and Monash University Keith Jerome Fred Hutchinson Cancer Research Center Usa Daniel Kuritzkes Brigham & Women s Hospital, Harvard Medical School Usa David Margolis University of North Carolina at Chapel Hill Usa Javier Martinez-Picado Aids Research Institute IrsiCaixa, Icrea, Uab Spain John Mellors University of Pittsburgh Usa Thumbi Ndung u University of Kwazulu-Natal South Africa Yiming Shao Chinese Center for Disease Control and Prevention China GL Scientific coordination Anna Laura Ross ANRS and IAS France Event organization Rosanne Lamplough, Jeanne Mencier, Olivier Rescanière, Tamara Torri 3

6 Programme GLOBAL 19th July 2014 SEARCH Opening Session Welcome and Introduction ARCHU Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France Jack Whitescarver, Office of AIDS Research, National Institutes of Health, GL Welcome Remarks Chair: Sharon Lewin, The Alfred Hospital, Monash University and Burnet Institute, Hon. David Davis, Minister for Health, Victorian Government, keynote address Chair: Steven Deeks, University of California, San Francisco, The Role of Therapeutic Vaccination in HIV Cure Strategies Jeffrey Lifson, Frederick National Laboratory for Cancer Research, Clearing HIV-Infected Cells: Kill Co-Chairs: Asier Saez-Cirion, Institut Pasteur, France Marcus Altfeld, Heinrich Pette Institute, Germany Overview Speaker Allogeneic Stem Cell Transplantation, Graft-versus-Host Disease and the Elimination of HIV Geoff Hill, Queensland Institute of Medical Research, OA1-1 A population of CD8 T cells is located in germinal centers that is functionally capable of mediating bispecific antibody mediated killing of HIV-infected T cells C. Petrovas, S. Ferrando-Martinez, A. Pegu, K. Boswell, M. Asokan, D. Ambrozak, D. Kotlyar, F. Docobo, M. Leal, E. Ruiz-Mateos, R. Koup Under embargo until 14:30 on 22 July OA1-2 Potent and Broadly Anti-HIV-1 Neutralizing Antibody VRC01 Inhibits HIV-1 Transmission from Plasmacytoid Dendritic Cells to CD4 T Lymphocytes B. Su, A. Lederle, G. Laumond, S. Schmidt, T. Decoville, C. Moog France 4

7 Programme GLOBAL 19th July 2014 SEARCH OA1-3 ARCHU HIV Controller CD4+ T cells preferentially express a public TCR clonotype that confers high avidity responses against Gag D. Benati, M. Galperin, O. Lambotte, A. Lim, B. Lemercier, M. Mukhopadhyay, M. Claireaux, S. Hendou, F. Boufassa, J.-F. Delfraissy, F. Arenzana-Seisdedos, L.A. Chakrabarti France GL OA1-4 Co-localization of Follicular SIV-specific CD8 T Cells with Tfh in the Germinal Centers of Chronically SIV Infected Rhesus Macaques is Associated with Enhanced Viral Control G. Mylvaganam, V. Velu, R.R. Amara Under embargo until 14:30 on 22 July Coffee Break Reversing Latent HIV: Shock Co-Chairs: Mathias Lichterfeld, Massachusetts General Hospital, Ben Berkhout, University of Amsterdam, The Netherlands Overview Speaker Epigenetic Regulation of HIV Latency Melanie Ott, Gladstone Institutes and University of California, San Francisco, OA2-1 Synergistic activation of HIV-1 expression by compounds releasing active positive transcription elongation factor b (P-TEFb) and by inducers of the NF-kB signaling pathway G. Darcis, A. Kula, S. Bouchat, K. Kabeya, N. Delacourt, C. Vanhulle, A. Burny, N. Clumeck, M. Moutschen, S. De Wit, C. Rouzioux, O. Rohr, C. Van Lint Belgium OA2-2 A new family of compounds that reactivate latent HIV in central memory T cells A. Bosque, C. Novis, L. Martins, A.B. Silva, P. Luciw, N. Archin, D. Margolis, V. Planelles OA2-3 Induction and Clearance of Latent HIV Infection: Modeling Viral Clearance by Immune Effectors using Cells from ART-treated Patients D. Margolis, C. Garrido, J.M. Sung, S. Lam, R. Bateson, B. Allard, N.P. Dahl, C. Cruz, P. Castillo-Caro, M. Ngo, J. Kuruc, A. Crooks, C.M. Rooney, C.M. Bollard, N.M. Archin, Collaboratory of AIDS Researchers for Eradication (CARE) 5

8 Programme GLOBAL 19th July 2014 SEARCH OA2-4 LB ARCHU The HDAC Inhibitor Romidepsin is Safe and Effectively Reverses HIV-1 latency in vivo as Measured by Standard Clinical Assays O.S. Søgaard, M.E. Graversen, S. Leth, C.R. Brinkmann, A.-S. Kjær, R. Olesen, P.W. Denton, S. Nissen, M. Sommerfelt, T.A. Rasmussen, L. Østergaard, M. Tolstrup Denmark Under embargo until 14:30 on 22 July 2014 GL Lunch Break Lunch will be provided in the foyer, in the poster exhibition area roundtable: Analytical Treatment Interruption in HIV Cure Research Chair: Edwina Wright, The Alfred Hospital, Monash University & Burnet Institute, Panelists: Judith Auerbach, University of California, San Francisco, Giulio Maria Corbelli, European AIDS Treatment Group, Italy Daniel Kuritzkes, Brigham and Women s Hospital, Harvard Medical School, Lars Østergaard, Aarhus University Hospital, Denmark Jeremy Sugarman, Johns Hopkins Berman Institute of Bioethics, Why Does HIV Persist on ART? Co-Chairs: Daniel Douek, Vaccine Research Center, NIAID, NIH, Sarah Read, Division of AIDS, NIAID, NIH, Overview Speaker Therapeutic Efficacy of Neutralizing Antibodies for HIV Dan Barouch, Beth Israel Deaconess Medical Center and Ragon Institute of MGH, MIT, and Harvard, OA3-1 Genetically characterizing the role of cell proliferation in maintaining persistent HIV during effective HIV therapy S. von Stockenstrom, L. Odevall, E. Sinclair, H. Hatano, P. Bacchetti, M. Somsouk, P.W. Hunt, S.G. Deeks, F.M. Hecht, S. Palmer 6

9 Programme GLOBAL 19th July 2014 SEARCH OA3-2 ARCHU TLR2 stimulation promotes HIV-1 infection of CD4+ T cells by increasing the susceptibility of CCR6- T cells to infection J.F. Bolduc, M. Ouellet, M.J. Tremblay Canada GL OA3-3 Interleukin-21 improves reconstitution of intestinal Th17 and Th22 cells and reduces residual inflammation in ART-suppressed SIV-infected Rhesus Macaques L. Micci, E. Ryan, C. McGary, S. Paganini, G. Silvestri, J. Brenchley, F. Villinger, M. Paiardini OA3-4 LB Cryptic transcription of HIV-RNA species from defective proviruses: A novel pathway for persistent immune activation in patients with HIV-1 infection and mechanism for persistent seropositivity despite undetectable levels of virus H. Imamichi, R.L. Dewar, D.W. Huang, D. Liang, C.A. Rehm, E. Paxinos, M. Brown, Y. Guo, C. Ludka, C. Hadigan, R.A. Lempicki, H.C. Lane Under embargo until 16:30 on 23 July OA3-5 LB IL-7 increases HIV-1 proviral integration in CD4+ T cells by inducing SAMHD1 phosphorylation, which can be blocked by Lck and PKCӨ inhibitors M. Coiras, M. Bermejo, E. Mateos, B. Descours, M. Benkirane, J. Alcami Spain Poster Exhibition & Networking Session During the poster session, we invite you to meet and discuss with the HIV cure 2014 scholars. The scholarship recipients can be identified by a red strip on their badges; the full list of scholarship recipients can be found on page 15. Drinks and light refreshments will be served. 7

10 Programme GLOBAL 20th July 2014 SEARCH roundtable: Preparedness for HIV Cure in Resource-Limited Settings Chair: Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS, Uganda ARCHU GL Panelists: Jintanat Ananworanich, US Military HIV Research Program, Robert Murphy, Northwestern University, Kenly Sikwese, Positive Health Outcomes, Zambia Mathurin Tejiokem, Pasteur Centre of Cameroon, Cameroon Joseph Tucker, University of North Carolina Project-China, China Coffee Break Where Does HIV Persist on ART? Co-Chairs: Luis Montaner, The Wistar Institute, Melissa Churchill, Burnet Institute, Overview Speaker Impact of Antiretroviral Treatment on HIV Reservoirs Christine Rouzioux, Université Paris Descartes, France OA4-1 The Immune Checkpoint Blockers PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify Distinct Cellular Reservoirs R. Fromentin, W. Bakeman, M.B. Lawani, G. Khoury, E. Sinclair, F.M. Hecht, S.G. Deeks, S.R. Lewin, J.-P. Routy, R.P. Sekaly, N. Chomont OA4-2 Following in vitro culture with myeloid dendritic cells, negative regulators of T-cell activation are expressed preferentially on latently infected CD4+ T-cells V.A. Evans, R.M. van der Sluis, N.A. Kumar, R.-P. Sekaly, R. Fromentin, N. Chomont, P.U. Cameron, S.R. Lewin OA4-3 Ultra-deep barcoded SIVmac239 to identify and quantify viral reservoirs and recrudescent viremia C. Fennessey, C. Reid, B. Keele Under embargo until 14:30 on 22 July

11 Programme GLOBAL 20th July 2014 SEARCH OA4-4 In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnuolo, J.V. Garcia ARCHU GL oa4-5 Simian Immunodeficiency Virus (SIV) infection of the macaque testis - An Immune privileged site W. Winnall, R. De Rose, C. Fernandez, S. Lloyd, M. Kramski, T. Amarasena, S. Alcantara, M. Hedger, S. Kent OA4-6 LB A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-naïve individuals harbour a large pool of latently infected CD4+ T cells F.A. Procopio, R. Fromentin, D. Kulpa, A. McNulty, A.-G. Bebin-Blackwell, M. Ramgopal, M.C. Strain, R.F. Siliciano, D.D. Richman, U. O Doherty, S. Palmer, J.D. Siliciano, F. Hecht, S.G. Deeks, R.-P. Sekaly, N. Chomont Lunch Break & Poster Exhibition Lunch will be provided in the foyer, in the poster exhibition area roundtable: Public and Private Partnerships in HIV Cure Research Co-Chairs: Sharon Lewin, The Alfred Hospital, Monash University and Burnet Institute, Zhi Hong, GlaxoSmithKline, Panelists: David Kaslow, PATH, Mike McCune, University of California, San Francisco, Closing Session Co-Chairs: Jean-François Delfraissy, ANRS, France Carl Dieffenbach, NIH, NIAID, Closing Lecture Targeting chromatin remodelling as a treatment for haematogical malignancies lessons we can learn for the treatment of latent HIV Miles Prince, Peter MacCallum Cancer Centre, IAS-ANRS Young Investigator Prize Ceremony Information on the award can be found on page Closing Remarks Françoise Barré-Sinoussi, Institut Pasteur and Inserm, France Jack Whitescarver, Office of AIDS Research, National Institutes of Health, 9

12 GL Poster Exhibition GLOBAL List of abstracts displayed ARCHU SEARCH Innate Immune Responses and Function during HIV Infection 1. HIV controllers have activated NK cells with a particular NK cell receptor profile and higher degranulation capacity D. Celine, P. Vermisse, F. Boufassa, A. Venet, A. Saez-Cirion, F. Barré-Sinoussi, O. Lambotte, D. Scott-Algara, ANRS EP36 HIV Controllers Study Group France 2. Modulation of HIV-induced TLR activation by ammonium compounds: new therapeutic strategy to reduce chronic immune activation? N. Smith, M. Dy, I. McCort, J.-P. Herbeuval France Virus-Specific Humoral Immunity 3. Evolution of neutralizing antibodies in acute heterosexually acquired HIV-1C infections T. Mduluza, K. Bedi, S. Dzoro, W.S. Mpoloka Zimbabwe Virus-Specific Cellular Immunity 4. Antiretroviral therapy preserves polyfunctional HIV-1-specific CD8 T cells with stem cell-like properties S. Vigano, J. Negron, F. Pereyra, E.S. Rosenberg, M. Lichterfeld, X. Yu Immune Responses in Resistant Cohorts: Long-Term Non-Progressors and Highly Exposed, Seronegative Individuals 5. Immunity to HIV GAG peptides and routine vaccine antigens in HIV-exposed uninfected infants in the ART era L.A.K. Afran Malawi Correlates of Immune Protection 6. A longitudinal assessment of host immunosuppressive responses in primary and chronic HIV infection M.-A. Jenabian, K. Vyboh, I. Kema, C. Kanagaratham, D. Radzioch, O. Allam, A. Ahmad, N. Gilmore, P. Ancuta, C. Tremblay, J.-P. Routy, Canadian Primary HIV infection study group Canada Mechanisms of Activation/Inflammation and Impact on Pathogenesis 7. Social Stress Prior to SIV or SHIV Infection Associates with Higher Viral Load and Lower CD4 Counts G. Neigh, T. Hayes, R. Trible, T. Vanderford, D. Carnathan, C. Harrell, K. Easley, B. Cervasi, M. Paiardini, G. Silvestri 8. Increased Immune Activation and Hypercoagulation after Gut Permeabilization in SIV-Infected African Green Monkeys I. Pandrea, J. Kristoff, T. Gaufin, R. Gautam, D. Ma, J. Estes, R. Tracy, C. Apetrei, G. Bagby, S. Nelson 9. Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the Adenosine Pathway in the Control of SIV-Related Immune Activation and Inflammation T. He, E. Brocca-Cofano, D. Gillespie, C. Xu, J. Kristoff, S. Ross, D. Ma, G. Haret-Richter, C. Rinaldo, C. Apetrei, E. Jackson, B. Macatangay, I. Pandrea Under embargo until 16:30 on 24 July SIV-infected rhesus macaques receiving suppressive cart have continued GI damage, inflammation, immune activation and persistent low-level viral replication within lymphoid tissues C. Deleage, J. McCune, T. Schacker, J. Estes Under embargo until 16:30 on 24 July

13 GL Poster Exhibition GLOBAL List of abstracts displayed ARCHU SEARCH HIV Replication and Pathogenesis in other Organs and Tissues 11. Envelope glycoprotein determinants of macrophage tropism during progressive HIV-1 subtype C infection K. Borm, M. Roche, K. Cashin, M.R. Jakobsen, A. Ellett, J. Sterjovski, J.K. Flynn, L. Gray, B. Lee, M. Churchill, P.R. Gorry 12. Preliminary Assessment of the Neurocognitive Effects of Vorinostat Administration in HIV Eradication K. Robertson, J. Kuruc, C. Gay, N. Archin, J. Eron, D. Margolis Viral Replication (including necessary cellular elements) 13. Naïve CD4+ T-cells are resistant to HIV infection in vitro in the presence of homeostatic signals G. Khoury, N. Kumar, A. Solomon, H. Lu, F. Wightman, P.U. Cameron, S.R. Lewin Viral Mechanisms of Persistence and Latency 14. Tropism alterations of HIV-1 subtype C strains for CD4+ T cell subsets J.K. Flynn, G. Paukovics, K. Borm, K. Cashin, A. Ellet, T. Spelman, M. Roche, M. Churchill, P.R. Gorry 15. HIV-1 establishes transcriptional latency in astrocytes in vitro and is responsive to HDACi L. Gray, C. Papaioannou, W.-J. Cheng, H. Lu, J. Jacobson, A. Ellett, C. Welsh, D. Purcell, F. Wightman, S. Wesselingh, P. Gorry, S. Lewin, M. Churchill 16. Alternative RNA splicing in latently infected T cells generates chimeric cellular: HIV mrnas with the potential to generate Tat and reactivate infection S. Sonza, J. Jacobson, T. Mota, M. Lee, J. Howard, S. Lewin, D. Purcell Under embargo until 14:30 on 22 July Activation of antigen-specific CD4+ T cells impacts on the establishment of the HIV DNA reservoir W. Hey-Cunningham, M. Bailey, A. Kelleher, K. Koelsch, J. Zaunders 18. Gag-mediated autophagy promotes CD4 T cell survival: a possible mechanism for HIV reservoir persistence (Late Breaker) H. Li, G. Hatfield, C.D. Pauza Host Cellular Factors and Latency 19. Drug Leads that Inhibit Vif and Enable APOBEC3G are Broadly Neutralizing of HIV1 Clades and Drug-resistant Strains H. Smith, R. Bennett, K. Prohaska, J. Slater 20. Co-culture of antigen presenting cells can induce latency in resting CD4+ T-cells N. Kumar, K. Cheong, V.A. Evans, J.L. Zhou, C.D.F. Pereira, J. Anderson, S.R. Lewin, P.U. Cameron 21. Possible clearance of transfusion-acquired nef-deleted attenuated HIV-1 infection by a long-term non-progressor with CCR5 Delta32 heterozygous and HLA-B57/DR13 genotype J. Zaunders, W.B. Dyer, M. Churchill, M.L. Munier, P. Cunningham, K. Suzuki, B. Wang, K. McBride, P.R. Gorry, N.K. Saksena, N. Seddiki, K. Koelsch, J.S. Sullivan, D.A. Cooper, S. Riminton, J. Learmont, A.D. Kelleher Under embargo until 14:30 on 22 July Targeting HIV Splicing and Translation in Latently Infected T cells: Contributing to a Cure G. Khoury, S. Ramarathinam, C. Mackenzie, D. Yurick, C. Sonza, T. Purcell, D. Purcell 11

14 GL Poster Exhibition GLOBAL List of abstracts displayed SEARCH Tissue Reservoirs 23. In vivo analysis of HIV persistence and immune responses in the brain J. Honeycutt, H. Vincent, A. Wahl, R.A. Spagnuolo, M. Swanson, K. Gordon, J.V. Garcia ARCHU 24. During the course of HIV infection tissue-resident effector memory CD4+ T cells are depleted but tissue-resident central memory CD4+ T cells are preserved A. Wahl, J.V. Garcia 25. Preferential infection of central memory T-cells that express CCR6 and CXCR3 in HIV-infected patients on ART may contribute to a larger HIV reservoir in rectal tissue (Late Breaker) J. Anderson, R. Fromentin, N. Chomont, E. Sinclair, G. Khoury, A. Solomon, M. Smith, P. Cameron, L. Epling, R. Hoh, F. Hecht, S. Deeks, S. Lewin Measurement of Reservoirs 26. Continued decay of HIV DNA species during 3 years of ART is not reflected by decay of HIV RNA in plasma W. Hey-Cunningham, K. Mcbride, J. Murray, J. Zaunders, S. Emery, D. Cooper, A. Kelleher, K. Koelsch, PINT Study Group 27. Distinct transcriptional regulators associated to the control of HIV reservoirs in central-memory CD4 T cells from Elite Controllers and long-term ARV treated patients or after IL-7 (Late Breaker) M. Pogliaghi, R. Zoorob, A. de Masson, A. Kirilovsky, V. Avettand, S. Lambert, V. Calvez, C. Rouzioux, C. Katlama, B. Autran France Targeting and Eradication of Reservoirs 28. Transcriptomic and proteomic screening of host genes modulated by HIV-1 in human macrophages: a highly sensitive strategy for the identification of new targets specific of HIV reservoirs A. Deshiere, M. Ouellet, M.J. Tremblay, CRI-LIRH Quebec City Canada 29. Immunotherapy depletion of T-cells in NHPs infected with SIV: Impact on viral load and T cell activation M. Di Mascio, S. Srinivasula, P. DeGrange, A. St. Claire, G. Duralde, L. Chandra, M. Piatak, I. Kim, C.H. Paik, J.F. Tisdale, R.E. Donahue, A. Woolfrey, H.C. Lane 30. RNA targeting the promoter region potently inhibits HIV-1 activation from latently infected cells K. Suzuki, T. Tsukamoto, K. Marks, D. Cooper, A. Kelleher 31. Apoptosis Activation of HIV Replication S. Khan, S. Zeichner 32. Viral specificity of small molecule latency disruptors K. Keck, S. Fernandez, A. Phan, J. Miranda 33. A dual-reporter cell line, expressing basal levels of Tat from its native IRES, reveals the poor specificity of current epigenetic modifying drugs for proviral HIV-1 activation J. Jacobson, K. Jarman, L. Harty, K. Lowes, K. Lackovic, D. Purcell 34. Modeling the effects of vorinostat in vivo on activation of latent HIV infection S. Lewin, K. Ruian, J. Elliott, A. Perelson 12

15 GL Poster Exhibition GLOBAL List of abstracts displayed ARCHU SEARCH 35. Development of T-Pharmacytes for the Targeted Eradication of HIV Reservoirs R.B. Jones, R. O Connor, S. Mueller, V. Vrbanac, S. Kumari, A. Tager, H. Wong, E. Jeng, E. Benko, C. Kovacs, B. Walker, D. Irvine 36. Quantification of Drug Transporters in Vaginal and Cervical Tissue Using a Novel Targeted Proteomics Approach: Implications for Small Molecule Disposition in Viral Reservoirs C.G. Thompson, J.K. Fallon, P.C. Smith, A.D.M. Kashuba 37. The kick-and-kill approach to a cure: Going for the kill by selective induction of apoptosis in latently infected cells (Late Breaker) M. Greenberg, H.M. Hanauske-Abel, T. Pe ery, B.M. Cracchiolo, P.E. Palumbo, J. Karn, M. Mathews 38. Multidose vorinostat in HIV-infected individuals on effective ART leads to an increase in regulatory T-cells but no change in inducible virus or HIV-specific T-cells (Late Breaker) F. Wightman, J.H. Elliot, A.E. Solomon, R. Fromentin, F.A. Procopio, J. Zeidan, T. Spelman, N. Chomont, P.U. Cameron, R.P. Sekaly, S.R. Lewin Host Genetics of Resistance and Susceptibility 39. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection M. Biasin, M. Sironi, R. Cagliani, F. Gnudi, I. Saulle, S. Ibba, G. Filippi, S. Yahyaei, C. Tresoldi, S. Riva, D. Trabattoni, L. De Gioia, S. Lo Caputo, F. Mazzotta, D. Forni, C. Pontremoli, J.A. Pineda, U. Pozzoli, A. Antonio Rivero-Juarez, A. Caruz, M. Clerici Italy Under embargo until 16:30 on 21 July 2014 Host Restriction Factors (including APOBEC and TRIM) 40. Quantification of Host Restriction Factor Gene Expression in HLA-B*57+ Individuals R.A. Raposo, M. Abdel-Mohsen, F.M. Hecht, C.D. Pilcher, S.K. Pillai, D.F. Nixon Therapeutic Vaccines 41. Therapeutic vaccine-induced Gag-specific CD8+ T cells under anti-retroviral therapy contribute to viral control in a macaque AIDS model M. Nakamura, Y. Takahara, S. Matsuoka, T. Miura, Y. Koyanagi, T. Matano Japan 42. Heteroclitic Human Immunodeficiency Virus Peptides Augment Cytokine Production, Increase Proliferation and Reduce PD-1 Expression by HIV-specific CD8+ T cells A. Adegoke, K. Gladney, M. Gallant, M. Grant Canada 43. Allogeneic assassination: NK cells demonstrate robust anti-hiv antibody-dependent activation against allogeneic targets S.L. Gooneratne, S.J. Kent, M.S. Parsons 44. Impact of RNA loaded Dendritic cell immunotherapy on HIV sequence Evolution in Chronic HIV Subjects Undergoing ATI (Late Breaker) I. Tcherepanova, J. Slagter-Jager, J. Harris, E. Vaughan, X. Feng, M. DeBenedette, J.-P. Routy, J. Jacobson, C. Nicolette, AGS study team 13

16 GL Poster Exhibition GLOBAL List of abstracts displayed ARCHU SEARCH Animal Models of Latency Reservoirs and Eradication 45. Use of A New, Transmitted Founder SIV Strain (SIVsmmFTq) to Achieve Control of Virus Replication with Conventional Antiretroviral Therapy (ART) in Rhesus Macaques (RMs) D. Ma, S. Ross, H. Li, G. Haret-Richter, R. Anand, J. Kristoff, C. Xu, J. Mellors, G. Shaw, B. Hahn, C. Apetrei Under embargo until 16:30 on 24 July 2014 Immune-Based Therapy Trials 46. A pilot study of the impact of rosuvastatin administration on residual chronic immune activation under antiretroviral therapy: the CESAR-IMEA trial L. Weiss, L. Assoumou, M.C. Chevalier, J.-L. Paul, M. Alhenc-Gelas, C. Didier, S. Taibi, M. Manea, P. Campa, P.-M. Girard, D. Costagliola France Eradication / Reservoir Depletion: Impact of ART and Non-ART Treatment 47. Impact of early initiation of combination antiretroviral therapy on measures of virus in peripheral blood of vertically HIV-1 infected children (Late Breaker) J. Brophy, T.-W. Chun, L. Samson, F. Kakkar, H. Soudeyns, M. Ostrowski, S. Mujib, J. Kim, P. Sandstrom, R. Harrigan, S. Read, A. Bitnun Canada Under embargo until 14:30 on 22 July Allogeneic bone marrow transplantation in two HIV-1 infected patients shows no detectable HIV-1 RNA or DNA, and a profound reduction in HIV-1 antibodies (Late Breaker) K.K. Koelsch, W.J. Hey-Cunningham, S.C. Sasson, C. Pearson, Y. Xu, M. Bailey, K.H. Marks, B.M. Hiener, S. Palmer, J. Zaunders, J.J. Post, S.T. Milliken, A.D. Kelleher, D.A. Cooper 49. Immunological Correlates of HIV-1 DNA Decline During Latency Reversal with Panobinostat in Patients on Suppressive cart (Late Breaker) M. Tolstrup, S. Vigano, R. Olesen, C. Brinkmann, M. Buzon, L. Østergaard, T. Rasmussen, M. Lichterfeld, O. Søgaard Denmark Novel Therapeutic Approaches (including gene therapy) 50. Agonistic antibody to human IL-21 promotes cytotoxic immune response to control viral infection Y.A. Leong, Y. Cui, Z. Chen, J. Toe, M. Pellegrini, S. Lewin, A. Landay, C. Mackay, D. Yu Mixed Methods, Integrated Approaches and Synergies in HIV Research and Intervention 51. Stakeholder engagement in HIV cure research - Lessons learned from other interventions and the way forward L. Ying-Ru, C. Chu, J. Ananworanich, J.-L. Excler, J. Tucker China Community Engagement in Research and Research Dissemination 52. Global Investment in HIV Cure Research and Development in 2013: Promising science and international collaborations E. Donaldson, K. Fisher, M. Warren * Full affiliations can be found in the abstract book 14

17 2014 Scholarship GLOBAL Recipients SEARCH Adeolu Oyemade Memorial University Adegoke ARCHU Canada Louise Afran Malawi Liverpool Wellcome Trust Malawi Karl Reiner Agbulos AIDS Society of the Philippines Philippines Jean-Francois Bolduc Université Laval Canada Katharina Borm Burnet Institute Giulio Maria Corbelli European AIDS Treatment Group Italy GL Miguel de Mulder Rougvie George Washington University Alexandre Deshiere Université Laval Canada Remi Fromentin VGTI Florida Federica Gnudi University of Milan Italy Lachlan Gray Burnet Institute Desire Habonimana YOWLI Burundi Burundi Tianyu He University of Pittsburgh Olimbi Hoxhaj Albanian Association of PLWHA Albania Jonathan Jacobson The University of Melbourne Babanina James Damian John Kelly The Institute for Global Youth Development Programs UK Community Advisory Board for HIV and HEP C and European AIDS Treatment Group United Kingdom Gabriela Khoury Monash University Georges Khoury University of Melbourne Ngo Bibaa Lundi-Anne Omam Reach Out Cameroon Cameroon Takafira Mduluza University of Zimbabwe Zimbabwe Midori Nakamura Moses Supercharger Nsubuga University of Tokyo/AIDS Research Center, National Institute of Infectious Diseases Joint Clinical Research Center Japan Uganda Opany Evans Odhiambo LVCT Health Kenya Bhoopathy P Swasti Health Resource Center India Mirko Paiardini Yerkes National Primate Research Center, Emory University 15

18 2014 Scholarship GLOBAL Recipients SEARCH Kristel Paola Ramirez Kumamoto University, Center for Valdez AIDS Research Juliet Reid Robert Reinhard Centre for All Families Positive Health (CAFPH) Institut des Recherches Cliniques de Montreal and Ontario HIV Treatment Network ARCHU Japan United Kingdom Canada GL Putthachard Saengtawan The Thai Red Cross AIDS Research Centre Thailand Yasir Saleem Youth Engagement and Education Council Iraq Rui Andre Saraiva Raposo The George Washington University Rae Ann Spagnuolo University of North Carolina at Chapel Hill Kamelia Stanoeva Medical University Sofia Bulgaria Bin Su INSERM U1110 and University of Strasbourg France Kumitaa Theva Das University of Science Malaysia Malaysia Christian Tjiam University of Western Filippo Turini San Raffaele Scientific Institute Italy Lieve Greta Vanleeuw Treatment Action Campaign South Africa Selena Vigano The Ragon Institute of MGH MIT and Harvard Angela Wahl University of North Carolina at Chapel Hill IAS-ANRS HIV Cure Young Investigator Award The US$2,000 IAS/ANRS Young Investigator Award is jointly funded by the IAS and the Agence Nationale de Recherche sur le sida et les hépatites virales (ANRS) to support young researchers who demonstrate innovation, originality, rationale and quality in the field of HIV/ AIDS research. The 2014 Prize is awarded to Gilles Darcis, Service of Molecular Virology, Institut de Biologie et de Médicine Moléculaires (IBMM) and Université Libre de Bruxelles (ULB), Belgium. 16

19 IAS Towards GLOBAL an HIV Cure Timeline SEARCH ARCHU GL July Towards an HIV Cure Symposium Towards an HIV Cure: Community Engagement Satellite, Melbourne June Towards an HIV Cure Symposium January 2014 Towards an HIV Cure Community Engagement Workshop, Chennai July 2012 Launch of the Global Scientific Strategy: Towards an HIV cure at the 2012 Symposium. Publication in Nature Reviews Immunology May 2013 Towards an HIV Cure Think-Tank: convene HIV cure researchers and scientists from other fields to encourage innovative approaches Establishment of the Working Group on Cost-Effectiveness Summer 2011 Launch of the Rome Statement: Major HIV/ AIDS Stakeholder s call for HIV cure research to be accelerated Early 2012 Establishment of the Working Group on Ethics, the Psychosocial Studies Group and the Industry Collaboration Group (ICG) Spring st Stakeholders Advisory Board meeting. The Advisory Board is co-chaired by Françoise Barré Sinoussi and Dr. Jack Whitescarver The International Scientific Working Group begins to develop a Global Scientific Strategy July 2010 Pre AIDS 2010 IAS workshop on HIV viral reservoirs Towards a Cure: HIV reservoirs and strategies to control them 17

20 2014 Towards an HIV Cure Symposium Time Saturday 19th July Sunday 20th July Time 9:00-9:30 Welcome Remarks Victoria Health Minister, David Davis MP 9:30-10:00 10:00-11:20 Keynote Address Jeffrey Lifson S1: Clearing HIV-infected Cells: Kill Invited Speaker: Geoff Hill 11:20-11:45 Break 11:45-13:05 S2: Reversing Latent HIV: Shock Invited Speaker: Melanie Ott 13:05-14:00 Lunch Roundtable: Preparedness for HIV Cure in Resource-Limited Settings 9:30-10:30 Break 10:30-11:00 S4: Where Does HIV Persist on ART? Invited Speaker: Christine Rouzioux Lunch Break Poster Exhibition 11:00-12:50 12:50-14:00 14:00-15:00 Roundtable: Analytical Treatment Interruption in HIV Cure Research Discussion: Public-Private Partnership for HIV Cure 14:00-14:30 15:00-16:35 S3: Why Does HIV Persist on ART? Invited Speaker: Dan Barouch Closing Session & IAS/ANRS Young Investigator Award Invited Speaker: Miles Prince 14:30-15:30 16:35-18:00 Poster Exhibition & Networking Session Symposium Sponsors: Office of AIDS Research towards an cure people focused science driven